scorecardresearch Skip to main content

Studies: Avastin may fight early breast cancers

Surprising results from two new studies may reopen the debate about the value of Avastin for breast cancer. AP/Genentech Inc., File

Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers found.

Avastin recently lost approval for treating advanced breast cancer, but the new studies suggest it might help women whose disease has not spread so widely. These were the first big tests of the drug for early breast cancer, and doctors were cautiously excited it showed potential to help.

In one study, just over one third of women given Avastin plus chemotherapy for a few months before surgery had no sign of cancer in their breasts when doctors went to operate, versus 28 percent of women given chemo alone. In the other study, more than 18 percent on Avastin plus chemo had no cancer in their breasts or lymph nodes at surgery versus 15 percent of those on chemo alone.

A big caveat, though: The true test is whether Avastin improves survival, and it is too soon to know that - both studies are still tracking the women’s health. The drug also has serious side effects.


“I don’t think it’s clear yet whether this is going to be a winner,’’ Dr. Harry Bear of Virginia Commonwealth University said of Avastin. But he said, “I don’t think we’re done with it.’’

Bear led one study, in the United States. Dr. Gunter von Minckwitz of the University of Frankfurt led the other in Germany. Results are in today’s New England Journal of Medicine.

Avastin is still on the market for some colon, lung, kidney, and brain tumors. In 2008, it won conditional US approval for advanced breast cancer because it seemed to slow the disease. Further research showed it did not meaningfully extend life and could cause heart, bleeding and other problems. The government revoked its approval for breast cancer in November.


Now doctors can prescribe Avastin for breast cancer, but insurers may not pay. Treatment can cost $10,000 a month. The drug is made by Genentech of California, part of the Swiss company Roche. It is still approved for treating advanced breast cancer in Europe and Japan.

The new studies tested it in a relatively novel way - before surgery. This is sometimes done to shrink tumors that seem inoperable, or to enable women to have just a lump removed instead of the whole breast.

The women in the studies had tumors that were large enough to warrant treatment besides surgery. Their cancers were not the type that can be treated by Herceptin, another widely used drug.

In the US. study, 1,200 women were given chemo or chemo plus infusions of Avastin. By the time of their surgery, no cancer could be found in the breasts of more than 34 percent of those given Avastin versus 28 percent of the others. (Surgeons still have to operate because they do not know the tumor is gone until they check tissue samples.)

The German study involved 1,900 women, including some with larger tumors. It used a stricter definition of cancer-free at surgery: no sign of disease in the breast or lymph nodes rather than just the breast. No cancer was seen in 18 percent of women on Avastin versus 15 percent of those given only chemo.

Different chemo drugs were used - a factor that might change Avastin’s effectiveness.